Citi Pharma Limited (CPHL), a Pakistani pharmaceutical company, has decided to venture into the real estate sector with the ...
The INHALE-3 trial (2024) compared the efficacy of an inhaled insulin regimen (Afrezza) plus long acting degludec insulin against usual care over 17 weeks among 123 adults. More participants using the ...
Inhaled technosphere insulin (TI) plus insulin degludec is noninferior to usual care among patients with type 1 diabetes (T1D), according to findings published in Diabetes Care. Inhaled TI is a ...
Doortje Rademaker, M.D., from the Amsterdam University Medical Center, and colleagues examined whether a treatment strategy of oral glucose-lowering agents is noninferior to insulin for prevention ...
Health care professionals should explore the use of glucagon-like peptide-1 receptor agonists (GLP1RAs) for cardiovascular risk reduction and their broader impacts on cardiometabolic health beyond ...
MONDAY, Dec. 16, 2024 (HealthDay News) -- For adults with type 1 diabetes, a regimen of inhaled Technosphere insulin (TI) plus insulin degludec is noninferior to usual care for glycemic control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback